dichloro(1,2-bis(4-hydroxyphenyl)ethylenediamine)platinum II: (-)-isomer most active on the growth of hormone dependent human MCF7 & MDA-MB231 breast cancer cell lines, ADJ/PC6 plasmacytoma of the Balb/C mouse & L5222 leukemia of the BDIX rat; RN & RRs from first source; RN refers to (meso)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 124467 |
| MeSH ID | M0126516 |
| Synonym |
|---|
| 91265-66-6 |
| dchpep ii |
| dichloro(1,2-bis(4-hydroxyphenyl)ethylenediamine)platinum ii |
| diaqua(meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)platinum(ii) sulfate |
| (-)-dichloro(1,2-bis(4-hydroxyphenyl)ethylenediamine)platinum(ii) |
| platinum, dichloro(4,4'-(1,2-diamino-1,2-ethanediyl)bis(phenol)-n,n')-, (sp-4-3-(r*,s*))- |
| (meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)diaqua-ptii sulfate |
| 4-[1,2-diamino-2-(4-hydroxyphenyl)ethyl]phenol;platinum(2+);dichloride |
| Excerpt | Relevance | Reference |
|---|---|---|
| " This result confirms our opinion that the strong in vivo activity of this drug on hormone-sensitive breast cancers is mediated by its estrogenic potency by analogy with high dosed steroidal and non-steroidal estrogens." | ( [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studies. Bernhardt, G; Gust, R; Hollstein, M; Koch, M; Krauser, R; Lux, F; Schlemmer, R; Schönenberger, H; Spruss, T, 1999) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||